Therapeutics News and Research

RSS

Clinical data of CU-201, CUDC-101 presented at EORTC-NCI-AACR Symposium

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of data in two poster presentations at the 22nd EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics," held in Berlin, Germany, November 16-19.

19 Nov 2010

BioCancell Therapeutics announces auction of common stock

BioCancell Therapeutics Inc. today announced that, pursuant to an effective registration statement on Form S-1 filed with the Securities and Exchange Commission, it intends to hold an auction in Israel on Thursday, November 18, 2010, for the sale of up to 617,000 units consisting, in the aggregate, of up to 6,170,000 shares of common stock, par value $0.01 per share, 3,085,000 Series 3 warrants and 3,085,000 Series 4 warrants.

18 Nov 2010

Aeterna presents data on AEZS-108 Phase 2 study for endometrial cancer at EORTC-NCI-AACR Symposium

Aeterna Zentaris Inc., earlier today, presented Phase 2 positive efficacy and safety data for its compound, AEZS-108, in advanced endometrial cancer.

18 Nov 2010

Neural differences may help explain prevalence of mental disorders in boys

Many mental health disorders, such as autism and schizophrenia, produce changes in social behavior or interactions. The frequency and/or severity of these disorders is substantially greater in boys than girls, but the biological basis for this difference between the two sexes is unknown.

18 Nov 2010

Anti-cancer drug smuggled using a nanocarrier past protective blood-brain barrier into brain tumours

Scientists in Germany have developed a way of smuggling an anti-cancer drug past the protective blood-brain barrier and into brain tumours and metastases using a nanocarrier - a tiny capsule specially designed to pass through cell membranes and deliver its anti-cancer drug to the cancer cell.

18 Nov 2010

Alnylam comments on Roche's corporate restructuring for RNAi therapeutics

Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, commented today on Roche's corporate restructuring and its implications on RNAi therapeutics.

18 Nov 2010

New anti-cancer drug targeting vitamin D receptor reduces PSA level in HRPC

A new anti-cancer drug aimed at vitamin D receptors on cancer cells has prompted encouraging responses in the levels of PSA (prostate specific antigen) in men with prostate cancer that has become resistant to hormonal therapies.

18 Nov 2010

Access Pharmaceuticals to present two oncology posters at CPR Conference

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that two oncology posters are being displayed this week at the Innovations in Cancer Prevention and Research Conference at the Austin Convention Center in Austin, TX.

18 Nov 2010

MK-4827 drug candidate shows promising anti-tumour activity in first human trial

A new drug that targets proteins responsible for helping cancer cells to repair damage to their DNA has shown promising anti-tumour activity in its first trial in humans.

18 Nov 2010

EMA reviews CTI's Pixuvri Marketing Authorization Application for NHL

Cell Therapeutics, Inc. announced today that CTI's Marketing Authorization Application seeking approval for Pixuvri (pixantrone dimaleate) for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's lymphoma was validated and accepted for review by the European Medicines Agency.

18 Nov 2010

Exelixis reports interim data of XL184 for metastatic castration-resistant prostate cancer

Exelixis, Inc. today reported interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

18 Nov 2010

Amsterdam 2010 third quarter total expense increases from EUR 4.4 million to EUR 4.7 million

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today provides its non-audited business update in compliance with the EU transparency directive. This report summarizes material events and AMT's financial position for the third quarter of 2010.

18 Nov 2010

Exelixis reports interim data from phase 2 RDT trial for epithelial ovarian cancer

Exelixis, Inc. today reported interim data from the cohort of patients with advanced epithelial ovarian cancer, primary peritoneal, or fallopian tube carcinoma treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

18 Nov 2010

Clinical trial shows dalfampridine tablets improve walking ability in MS patients

Acorda Therapeutics, Inc. today announced that data from the second of two pivotal dalfampridine extended release tablets Phase 3 clinical trials in multiple sclerosis (MS) were published in the October 2010 edition of Annals of Neurology.

18 Nov 2010

Myrexis presents data on MPC-9528 cancer metabolism inhibitor at EORTC/NCI/AACR Symposium

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today presented two posters at the 22nd European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) and American Association for Cancer Research (AACR) Symposium on "Molecular Targets and Cancer Therapeutics," in Berlin, Germany.

18 Nov 2010

VX-770 drug candidate improves lung function in people with cystic fibrosis

In a study published in this week's New England Journal of Medicine, treatment with a new drug candidate known as VX-770 resulted in improvements in lung function and markers of disease in a Phase 2 clinical trial of 39 people with cystic fibrosis (CF). There were no discontinuations due to adverse events in the study, and the frequency of adverse events was similar across the study groups.

18 Nov 2010

Low back pain care initiated with chiropractic doctor saves 40% on health care costs

A new study finds that low back pain care initiated with a doctor of chiropractic (DC) saves 40% on health care costs when compared with care initiated through a medical doctor (MD), the American Chiropractic Association (ACA) announced today. The study, featuring data from 85,000 Blue Cross Blue Shield beneficiaries, concludes that insurance companies that restrict access to chiropractors for low back pain treatment may inadvertently pay more for care than they would if they removed such restrictions.

17 Nov 2010

Aeterna Zentaris presents results of orally active compounds with anti-tumor effects at EORTC-NCI-AACR Symposium

Aeterna Zentaris Inc. today presented posters on encouraging preclinical results for AEZS-129 and AEZS-132, two novel orally active compounds with anti-tumor effects.

17 Nov 2010

Targeted therapies could treat a broad range of cancers: Research

Targeted cancer therapies such as trastuzumab (Herceptin), gefitinib (Iressa) and erlotinib (Tarceva) could be used to treat a wider range of cancers than previously thought, according to new research presented today (Wednesday) at the 22nd EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Berlin.

17 Nov 2010

MedImmune to present data on oncology portfolio at two medical congresses in Europe and the U.S.

Today, MedImmune announced that researchers will present data from its oncology portfolio, including new clinical data, at two upcoming medical congresses in Europe and the United States.

17 Nov 2010

Therapeutics News and Research

Clinical data of CU-201, CUDC-101 presented at EORTC-NCI-AACR Symposium

BioCancell Therapeutics announces auction of common stock

Aeterna presents data on AEZS-108 Phase 2 study for endometrial cancer at EORTC-NCI-AACR Symposium

Neural differences may help explain prevalence of mental disorders in boys

Anti-cancer drug smuggled using a nanocarrier past protective blood-brain barrier into brain tumours

Alnylam comments on Roche's corporate restructuring for RNAi therapeutics

New anti-cancer drug targeting vitamin D receptor reduces PSA level in HRPC

Access Pharmaceuticals to present two oncology posters at CPR Conference

MK-4827 drug candidate shows promising anti-tumour activity in first human trial

EMA reviews CTI's Pixuvri Marketing Authorization Application for NHL

Exelixis reports interim data of XL184 for metastatic castration-resistant prostate cancer

Amsterdam 2010 third quarter total expense increases from EUR 4.4 million to EUR 4.7 million

Exelixis reports interim data from phase 2 RDT trial for epithelial ovarian cancer

Clinical trial shows dalfampridine tablets improve walking ability in MS patients

Myrexis presents data on MPC-9528 cancer metabolism inhibitor at EORTC/NCI/AACR Symposium

VX-770 drug candidate improves lung function in people with cystic fibrosis

Low back pain care initiated with chiropractic doctor saves 40% on health care costs

Aeterna Zentaris presents results of orally active compounds with anti-tumor effects at EORTC-NCI-AACR Symposium

Targeted therapies could treat a broad range of cancers: Research

MedImmune to present data on oncology portfolio at two medical congresses in Europe and the U.S.

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News